Commissioning of Phase II Therapeutic Albumin & Plasma Derivatives Production Line at Nojin Refinery

Following the successful completion of comprehensive validation protocols and aseptic qualification trials, Nojin Zist Pharmed has officially commissioned the second expansion phase of its specialized plasma fractionation refinery.

This cutting-edge industrial facility is engineered to process human plasma into vital therapeutic derivatives, specifically Human Albumin 20% (Albojin) and high-titer Intravenous Immunoglobulins (IVIg). Operating under stringent cleanroom Grade A/B conditions and equipped with automated viral inactivation chambers, the facility dramatically bolsters healthcare security and domestic availability of plasma-derived medicinal products (PDMPs).

Dr. Keyvan Mansouri, Chief Technical Officer, emphasized: ‘The localized commissioning of this advanced cold ethanol fractionation train guarantees reproducible yield, superior protein integrity, and absolute compliance with international pharmacopoeial standards.’